ArticleInternational journal of nanomedicine2009
Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits.
Article in International journal of nanomedicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 92 citations in OpenAlex.
- Ex Vivo Evaluation of Poly(Solketal Acrylate) Nanoparticles for Intravitreal Drug Delivery to the Posterior Eye Segment.Macromolecular rapid communications · 2026Article
- Magnetically Controlled Intraocular Delivery of Dexamethasone Using Silica-Coated Magnetic Nanoparticles.ACS omega · 2024Article
- Active Transport and Ocular Distribution of Intravitreally Injected Liposomes.Translational vision science & technology · 2023Article
- Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.Pharmaceutics · 2023Review
- Nanoparticles: Taking a Unique Position in Medicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.Gels (Basel, Switzerland) · 2022Review
- An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.International journal of nanomedicine · 2022Review
- Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study.Pharmaceutics · 2021Article
- Tissue Engineering Meets Nanotechnology: Molecular Mechanism Modulations in Cornea Regeneration.Micromachines · 2021Review
- A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability.Pharmaceutics · 2021Article
- Ocular prodrugs: Attributes and challenges.Asian journal of pharmaceutical sciences · 2021Review
- Steroid-eluting contact lenses for corneal and intraocular inflammation.Acta biomaterialia · 2020Article
- Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis.Cellular and molecular life sciences : CMLS · 2019Review
- Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein.Pharmaceutics · 2019Article
- Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.Journal of ophthalmology · 2018Article
- Nanotechnology in retinal drug delivery.International journal of ophthalmology · 2018Review
- Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.Scientific reports · 2017Article
- Nanomedicine in the application of uveal melanoma.International journal of ophthalmology · 2016Review
- Delivery of dexamethasone from bioactive nanofiber matrices stimulates odontogenesis of human dental pulp cells through integrin/BMP/mTOR signaling pathways.International journal of nanomedicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to investigate the tolerance and pharmacokinetics of dexamethasone (DEX)-loaded poly(lactic acid-co-glycolic acid) nanoparticles (DEX-NPs) in rabbits after intravitreal injection. The DEX-NPs were prepared and characterized in terms of morphology, particle size and size distribution, encapsulation efficiency, and in vitro release. Ophthalmic investigations were performed, including fundus observation and photography, intraocular pressure measurement, and B-scan ocular ultrasonography. There were no abnormalities up to 50 days after administration of DEX-NPs in rabbits. The DEX concentrations in plasma and the ocular tissues such as the cornea, aqueous humor, lens, iris, vitreous humor, and chorioretina were determined by high-pressure liquid chromatography. The DEX-NPs maintained a sustained release of DEX for about 50 days in vitreous and provided relatively constant DEX levels for more than 30 days with a mean concentration of 3.85 mg/L(-1). Based on the areas under the curve, the bioavailability of DEX in the experimental group was significantly higher than that in the control group injected with regular DEX. These results suggest that intravitreal injection of DEX-NPs lead to a sustained release of DEX with a high bioavailability, providing a basis for a novel approach to the treatment of posterior segment diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.